Status:
COMPLETED
Real Life Second-Line Nivolumab in Advanced Non-Small Cell Lung Cancer
Lead Sponsor:
University Hospital, Brest
Conditions:
NSCLC
Eligibility:
All Genders
18+ years
Brief Summary
Data regarding nivolumab as second line treatment in advanced non-small cell lung cancer (NSCLC) are based on selected populations and might not reflect daily practice. Investigators aimed at assessin...
Eligibility Criteria
Inclusion
- advanced NSCLC (stage IIIB-IV)
- failure of at least one line of chemotherapy.
- age ≥18 years,
- initiation of nivolumab between 01/09/2015 and 30/09/2016.
Exclusion
- nivolumab initiation after October 2016
- prior involvement in an immunotherapy trial
- refusal to participate.
Key Trial Info
Start Date :
April 14 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2017
Estimated Enrollment :
259 Patients enrolled
Trial Details
Trial ID
NCT04858204
Start Date
April 14 2017
End Date
November 1 2017
Last Update
April 26 2021
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
CHRU de Brest
Brest, France, 29609
2
CH DINAN
Dinan, France, 22101
3
Centre Hospitalier de Bretagne Sud
Lorient, France, 56100
4
CHU de Rennes
Rennes, France, 35000